2011-8521. Cooperative Agreement With the University of Mississippi's National Center for Natural Products Research (U01) To Develop and Disseminate Botanical Natural Product Research With an Emphasis on Public Safety  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA) is announcing the availability of grant funds for the support of a cooperative agreement with the University of Mississippi's National Center for Natural Products Research (UM-NCNPR). The goal of the cooperative agreement is to promote the efficient development and dissemination of natural products research and science and the programs developed under the agreement will complement the diverse activities of both the public and private sectors.

    DATES:

    Important dates are as follows:

    1. The application due date is May 1, 2011.

    2. The anticipated start date is June 1, 2011.

    3. The opening date is April 11, 2011.

    4. The expiration date is May 2, 2011.

    For Further Information and Additional Requirements Contact:

    Scientific/Programmatic Contacts:

    Jeanne I. Rader, Center for Food Safety and Applied Nutrition (HFS-715), 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1786, FAX: 301-436-2622, e-mail: Jeanne.Rader@fda.hhs.gov; or

    Steven L. Robbs, Center for Food Safety and Applied Nutrition (HFS-006), 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2146, FAX: 301-436-2618, e-mail: Steven.Robbs@fda.hhs.gov; or

    LaQuia S. Geathers, Center for Food Safety and Applied Nutrition (HFS-680), 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-2821, FAX: 301-436-2629, e-mail: LaQuia.Geathers@fda.hhs.gov.

    Grants Management Contact:

    Vieda Hubbard, Office of Acquisitions and Grants Services (HFA-500), 5630 Fishers Lane, Rm. 2141, Rockville, MD 20857, 301-827-7177, FAX: 301-827-7101, e-mail: Vieda.Hubbard@fda.hhs.gov.

    For more information on this funding opportunity announcement (FOA) and to obtain detailed requirements, please refer to the full FOA located at http://grants2.nih.gov/​grants/​guide and http://www.fda.gov/​Food/​NewsEvents/​default.htm.

    End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    I. Funding Opportunity Description

    RFA-FD-11-004

    Catalog of Federal Domestic Assistance Number(s): 93.103 https://www.cfda.gov.

    A. Background

    The primary focus of the UM-NCNPR/FDA cooperative agreement is to develop and disseminate botanical natural product research with an emphasis on public safety according to the needs of FDA. The cooperative research, education, and outreach programs developed by UM-NCNPR will address scientific issues related to the safety of botanical dietary supplements (BDS) and botanical ingredients and will complement the diverse activities of both the public and private sectors.

    B. Research Objectives

    This cooperative agreement will define the research projects, workshops, conferences, partnerships with academia, industry, non-governmental organizations, and international organizations and other activities on which the FDA and UM-NCNPR will collaborate. Specifically, this cooperative agreement will provide continued support so that UM-NCNPR can:

    • Assist in the identification and development of a list of BDS and botanical ingredients, based on safety concerns, trends, and knowledge of botanicals being marketed in the United States, to prioritize for further research.
    • Acquire, validate, and characterize authenticated reference materials, including raw and processed plant materials and purified natural products of relevance to FDA, for evaluation of their safety.
    • Exchange technical and scientific information, analytical methods, and reference material with FDA scientists and other stakeholders.
    • Collaborate with FDA scientists in research areas of mutual interest.
    • Coordinate scientific workshops and conferences on BDS-related topics of public health relevance to address high priority science and research needs.

    C. Eligibility Information

    NCNPR has the unique capability to bring together diverse scientific Start Printed Page 19997expertise on BDS and botanical ingredients from: (1) The faculty in the UM School of Pharmacy, including researchers in the Departments of Pharmacognosy, Medicinal Chemistry, Pharmaceutics, Pharmacology, and the Research Institute of Pharmaceutical Sciences; (2) research scientists in the U.S. Department of Agriculture/Agricultural Research Service's (USDA/ARS) National Products Utilization Research unit who are physically co-located and programmatically integrated in the UM-NCNPR; (3) close academic links and historical collaborations with agriculture and botanical programs and facilities within the UM system; (4) successful research collaborations with the dietary supplement industry; and (5) established formal agreements with several international academic institutions.

    These collaborations give UM-NCNPR the unique ability to provide essential scientific expertise and botanical and chemical resources that will continue to assist FDA in its mission to ensure the safety of BDS and botanical ingredients.

    FDA believes that continued support of UM-NCNPR is appropriate because it is uniquely qualified to fulfill the objectives of the proposed cooperative agreement. FDA has determined that UM-NCNPR is the only institution with the unique capability of providing a broad range of highly relevant scientific expertise and facilities that are physically co-located and singularly dedicated to natural products research. UM is a comprehensive research institution with numerous academic programs relevant to natural products.

    II. Award Information/Funds Available

    A. Award Amount

    The estimated amount of support in Fiscal Year (FY) 2011 will be for up to $2.1 million (direct plus indirect costs), with the possibility of 4 additional years of support for up to $2.5 million per year, subject to the availability of funds. Future year amounts will depend on annual appropriations and successful performance.

    B. Length of Support

    The award will provide 1 year of support, with the possibility of 4 additional years of support, contingent upon satisfactory performance in the achievement of project and program reporting objectives during the preceding year and the availability of Federal FY appropriations.

    III. Electronic Application, Registration, and Submission

    Only electronic applications will be accepted. To submit an electronic application in response to this FOA, applicants should first review the full announcement located at http://www.fda.gov/​Food/​NewsEvents/​default.htm or http://grants2.nih.gov/​grants/​guide. (FDA has verified the Web site addresses throughout this document, but FDA is not responsible for any subsequent changes to the Web sites after this document publishes in the Federal Register.) For all electronically submitted applications, the following steps are required.

    • Step 1: Obtain a Dun and Bradstreet (DUNS) Number.
    • Step 2: Register With Central Contractor Registration.
    • Step 3: Obtain Username & Password.
    • Step 4: Authorized Organization Representative (AOR) Authorization.
    • Step 5: Track AOR Status.
    • Step 6: Register With Electronic Research Administration (eRA) Commons.

    Steps 1 through 5, in detail, can be found at http://www07.grants.gov/​applicants/​organization_​registration.jsp. Step 6, in detail, can be found at https://commons.era.nih.gov/​commons/​registration/​registrationInstructions.jsp. After you have followed these steps, submit electronic applications to: http://www.grants.gov.

    Start Signature

    Dated: April 1, 2011.

    Leslie Kux,

    Acting Assistant Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2011-8521 Filed 4-8-11; 8:45 am]

    BILLING CODE 4160-01-P

Document Information

Published:
04/11/2011
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
2011-8521
Dates:
Important dates are as follows:
Pages:
19996-19997 (2 pages)
Docket Numbers:
Docket No. FDA-2011-N-0012
PDF File:
2011-8521.pdf